Pancreatic Cancer Research

Clinical trialObservationalUnknown

Biomarker Study in Pancreatic Neuroendocrine Tumours

Prospective Longitudinal Biomarker Study in Pancreatic Neuroendocrine Tumours

Outcome
Outcome unknown
Phase
Observational
Status
Unknown
Study type
Observational
Start
1 May 2017
Listed end
1 January 2022
Enrollment
30 participants
Sites
1
Primary outcomes
Correlation between FDG-PET and tumor biology
Sponsor type
Academic / other
Results posted
No
Last update
25 August 2017

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The biology of pancreatic neuroendocrine tumors can change during the disease course. This evolution of disease can manifest through increases in tumor proliferation rate, resistance to medical therapy and/or a change in tumor hormone secretion. This study aims to characterize how the biology of pancreatic neuroendocrine tumors change over time, measured by; patient symptoms, biochemistry, contrast enhanced computed tomography, FDG-PET and core needle biopsy with histopathological analysis (Ki67 index and tumor cell differentiation). Uptake on 18F-FDG-PET will be correlated directly to tumor cell proliferation rate. Fraction of patients with spatial heterogeneity in FDG uptake as well as metachronous changes in all collected data will be documented. Biomaterial from whole blood and core needle biopsies will be characterized on the molecular level, and those findings will be integrated to the above specified clinical parameters.